$ESLA
Estrella Immunopharma, Inc. Stock $esla

$esla Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000121390024082374 Filed on September 27, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$550.7K	$424.5K	$3.201M
YoY Change	-60.29%	4144.5%	382.69%
% of Gross Profit
Research & Development	$2.826M	$3.525M	$4.109M
YoY Change	484.53%		-60.68%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$3.377M	$3.949M	$7.310M
YoY Change	80.53%	2223.21%	-34.23%
Operating Profit	-$3.400M		-$7.310M
YoY Change	81.77%		-34.23%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.500M
YoY Change	2900.0%
Pretax Income	-$3.377M	-$3.949M	-$7.310M
YoY Change		7090.36%	-34.23%
Income Tax		$1.630K	$1.625K
% Of Pretax Income
Net Earnings	-$3.377M	-$3.951M	-$7.312M
YoY Change	80.53%	5098.5%	-34.21%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09		-$0.27
Diluted Earnings Per Share	-$0.09	-$0.10	-$0.27
COMMON SHARES
Basic Shares Outstanding	36.19M shares	36.38M shares	27.10M shares
Diluted Shares Outstanding	36.21M shares		27.10M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.798M	$4.165M	$4.165M
YoY Change	-91.88%	13784.77%	68.02%
Cash & Equivalents	$1.800M	$4.200M	$4.165M
Short-Term Investments
Other Short-Term Assets	$437.6K	$288.8K	$288.8K
YoY Change	-91.6%	220.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.235M	$4.454M	$4.454M
YoY Change	-91.83%	3343.17%	61.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.500M	$0.00	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$1.500M	$0.00	$0.00
YoY Change	-50000100.0%	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$2.235M	$4.454M	$4.454M
Total Long-Term Assets	$1.500M	$0.00	$0.00
Total Assets	$3.735M	$4.454M	$4.454M
YoY Change	-86.34%	-55.11%	47.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.000K	$0.00	$0.00
YoY Change	-99.95%	-100.0%	-100.0%
Accrued Expenses	$2.936M	$135.5K	$135.5K
YoY Change	10503.68%		-67.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.989M	$180.7K	$180.7K
YoY Change	-82.7%	-87.38%	-98.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$0.00		$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.989M	$180.7K	$180.7K
Total Long-Term Liabilities	$0.00		$0.00
Total Liabilities	$2.989M	$180.7K	$180.7K
YoY Change	-82.7%	-93.96%	-98.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$22.90M	-$19.50M
YoY Change	62.88%	591.31%
Common Stock	$3.661K	$24.13M
YoY Change	4.01%	16991592.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$504.9K	$354.4K
YoY Change
Treasury Stock Shares
Shareholders Equity	$746.3K	$4.273M	$4.273M
YoY Change
Total Liabilities & Shareholders Equity	$3.735M	$4.454M	$4.454M
YoY Change	-86.34%	-55.11%	47.08%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$3.377M	-$3.951M	-$7.312M
YoY Change	80.53%	5098.5%	-34.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$2.217M	-$291.5K	-$16.07M
YoY Change	705.79%	38.82%	1102.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$4.961M
YoY Change	-100.0%	-100.0%	-1916.62%
Cash From Investing Activities		$0.00	$4.961M
YoY Change		-100.0%	-1916.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$150.5K	-270.4K	$12.79M
YoY Change	-100.75%	-242.29%
NET CHANGE
Cash From Operating Activities	-$2.217M	-291.5K	-$16.07M
Cash From Investing Activities		0.000	$4.961M
Cash From Financing Activities	-$150.5K	-270.4K	$12.79M
Net Change In Cash	-$2.368M	-561.9K	$1.686M
YoY Change	-112.05%	-643523539894272900.0%	-204.79%
FREE CASH FLOW
Cash From Operating Activities	-$2.217M	-$291.5K	-$16.07M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27103964	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	305748	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-40608
CY2024	dei	Entity Registrant Name EntityRegistrantName	ESTRELLA IMMUNOPHARMA, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-1314502
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	5858 Horton Street
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 370
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Emeryville
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94608
CY2024	dei	City Area Code CityAreaCode	(510)
CY2024	dei	Local Phone Number LocalPhoneNumber	318-9098
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Public Float EntityPublicFloat	40271957	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36190896	shares
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024	dei	Auditor Name AuditorName	Macias Gini & O’Connell LLP
CY2024	dei	Auditor Location AuditorLocation	Walnut Creek, CA
CY2024	dei	Auditor Firm AuditorFirmId	324
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4165428	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2479146	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	288761	usd
CY2023Q2	esla	Extension Note Receivable Current ExtensionNoteReceivableCurrent	273066	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	4454189	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	2752212	usd
CY2023Q2	us-gaap	Deferred Costs DeferredCosts	276187	usd
CY2024Q2	us-gaap	Assets Assets	4454189	usd
CY2023Q2	us-gaap	Assets Assets	3028399	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	131823	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	398781	usd
CY2024Q2	esla	Franchise Tax Payables Current FranchiseTaxPayablesCurrent	4134	usd
CY2023Q2	esla	Franchise Tax Payables Current FranchiseTaxPayablesCurrent	4297	usd
CY2024Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	40744	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	180701	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9758224	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12725	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12725	usd
CY2024Q2	us-gaap	Liabilities Liabilities	180701	usd
CY2023Q2	us-gaap	Liabilities Liabilities	9770949	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36610870	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36610870	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	978243	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	978243	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	3661	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	98	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	24124543	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	445905	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19500276	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12188553	usd
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	321794	shares
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2024Q2	us-gaap	Treasury Stock Value TreasuryStockValue	354440	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	4273488	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-11742550	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4454189	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3028399	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4108925	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10451212	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3201173	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	663190	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	7310098	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	11114402	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-7310098	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-11114402	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7310098	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11114402	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1625	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7311723	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11114402	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-36.35
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27103964	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	305748	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1039843	usd
CY2024	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	14750000	usd
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12725	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1194653	usd
CY2024	esla	Stock Issued During Period Value Issuance Of Common Stock For Pipe Investment StockIssuedDuringPeriodValueIssuanceOfCommonStockForPIPEInvestment	10000000	usd
CY2024	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	473977	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1801200	usd
CY2024	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	354440	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7311723	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	4273488	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-7311723	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11114402	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	1194653	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	409595	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	149994	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-833333	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-9333146	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	8387559	usd
CY2024	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-449958	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	122594	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-18000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	22000	usd
CY2024	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-138	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3200	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16068306	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1336121	usd
CY2024	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	112298	usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	273066	usd
CY2024	esla	Proceeds From Cash Released From Trust Account ProceedsFromCashReleasedFromTrustAccount	5072945	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4960647	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-273066	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1525013	usd
CY2024	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	10000000	usd
CY2024	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9020000	usd
CY2024	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	300000	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	300000	usd
CY2024	esla	Payment Of Redemption Payable PaymentOfRedemptionPayable	5072945	usd
CY2024	esla	Proceeds From Business Combination ProceedsFromBusinessCombination	726339	usd
CY2024	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	354440	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12793941	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1686282	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1609187	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2479146	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4088333	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4165428	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2479146	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	2663	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	276187	usd
CY2023	esla	Recognitionof Related Party Operating Rightofuse Asset And Lease Liability RecognitionofRelatedPartyOperatingRightofuseAssetAndLeaseLiability	48988	usd
CY2024	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	5000000	usd
CY2024	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	730000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4200000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19500000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	20100000	usd
CY2023Q3	esla	Deducting Amount DeductingAmount	5100000	usd
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	467122	shares
CY2023Q3	esla	Repayment Of Working Capital Loans RepaymentOfWorkingCapitalLoans	700000	usd
CY2023Q4	esla	Fees For Achieve Milestones FeesForAchieveMilestones	33000000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Significant items subject to such estimates and assumptions include stock-based compensation, and deferred income tax asset valuation and allowances.</p>
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2214993	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29114368	shares
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of two cash accounts in a financial institution located in the United States. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks. The Federal Deposit Insurance Corporation (FDIC) provides standard insurance coverage of $250,000 per insured bank for each account ownership category. As of June 30, 2024, and 2023, the Company had not experienced losses on these accounts. As of June 30, 2024, and 2023, the Company had deposited $4,019,813 and $2,479,146, respectively, with financial institutions in the United States. Of these balances, $3,758,670 and $2,229,146, respectively, were not covered by deposit insurance. While management believes that these financial institutions are of high credit quality, it also continually monitors their creditworthiness.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities Investor Protection Corporation (SIPC) provides standard insurance coverage of $500,000 per brokerage account, which includes $250,000 for cash balances. As of June 30, 2024, and 2023, the Company maintained $145,615 and $0, respectively, in its brokerage account, with the entire balance covered by SIPC insurance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	3758670	usd
CY2023	us-gaap	Interest Income Deposits With Financial Institutions InterestIncomeDepositsWithFinancialInstitutions	2229146	usd
CY2024	us-gaap	Payments For Brokerage Fees PaymentsForBrokerageFees	145615	usd
CY2023	us-gaap	Payments For Brokerage Fees PaymentsForBrokerageFees	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024	esla	Proceeds From Business Combination ProceedsFromBusinessCombination	726339	usd
CY2024	esla	Funds Held In Upt Ds Trust Account FundsHeldInUPTDsTrustAccount	8138230	usd
CY2024	esla	Funds Held In Operating Cash Account FundsHeldInOperatingCashAccount	9782	usd
CY2024	esla	Payment Of Redemption Payable PaymentOfRedemptionPayable	5072945	usd
CY2024	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	467122	shares
CY2024	esla	Payments Of Transaction Costs Incurred By Uptd PaymentsOfTransactionCostsIncurredByUPTD	1640128	usd
CY2024	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	708600	usd
CY2024	esla	Reverse Recapitalization Exchange Ratio ReverseRecapitalizationExchangeRatio	0.002407	pure
CY2023Q2	esla	Extension Note Receivable Current ExtensionNoteReceivableCurrent	273066	usd
CY2024Q2	us-gaap	Assets Held In Trust AssetsHeldInTrust	45511	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	121235	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	398781	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10241	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	347	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	131823	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	398781	usd
CY2023Q2	us-gaap	Purchase Obligation PurchaseObligation	50000000	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.20	pure
CY2024	esla	Budgeted Amount BudgetedAmount	0.50	pure
CY2024	esla	Development Milestone Payment DevelopmentMilestonePayment	50000	usd
CY2024Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	0	usd
CY2022Q2	us-gaap	Financial Services Liabilities FinancialServicesLiabilities	10000000	usd
CY2024	esla	Interest Charges InterestCharges	0.015	pure
CY2024Q2	us-gaap	Deposits Deposits	1500000	usd
CY2024	esla	Additional Invoice Per Patient AdditionalInvoicePerPatient	1375000	usd
CY2024	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	27500000	usd
CY2024	esla	Mile Stone Fees MileStoneFees	2000000	usd
CY2023Q2	us-gaap	Investment Owned Percent Of Net Assets InvestmentOwnedPercentOfNetAssets	0.921	pure
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024	us-gaap	Payments For Rent PaymentsForRent	20000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	22000	usd
CY2024	esla	Shares Based On An Exchange Ratio SharesBasedOnAnExchangeRatio	0.002407	pure
CY2024	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.08	pure
CY2024Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	1
CY2024Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	1
CY2023Q3	esla	Shares Based On An Exchange Ratio SharesBasedOnAnExchangeRatio	0.002407	pure
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	978243	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	978243	shares
CY2024Q2	esla	Common Stock Outstanding Prior To Reverse Recapitalization CommonStockOutstandingPriorToReverseRecapitalization	2329920	shares
CY2024Q2	esla	Common Stock Subject To Possible Redemption CommonStockSubjectToPossibleRedemption	628688	shares
CY2024Q2	esla	Shares Issued Uponthe Reverse Recapitalization SharesIssuedUpontheReverseRecapitalization	1701232	shares
CY2024	esla	Number Of Days Receive Investor After The Date Of Closing Of Business Comnination NumberOfDaysReceiveInvestorAfterTheDateOfClosingOfBusinessComnination	P30Y
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	1.1
CY2022Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1638381	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1194653	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	409595	usd
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1194653	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	409595	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1600000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.001
CY2022Q2	us-gaap	Share Price SharePrice	0.11
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.20	pure
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.03	pure
CY2022Q2	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	15000	usd
CY2024Q2	us-gaap	Other Liabilities OtherLiabilities	0	usd
CY2023Q2	us-gaap	Other Liabilities OtherLiabilities	12725	usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3568955	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.46
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	935873	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.46
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2633082	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.46
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2633082	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.46
CY2024	esla	Reverse Recapitalization Exchange Ratio ReverseRecapitalizationExchangeRatio	0.002407	pure
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7310098	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11114402	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1625	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1625	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.062	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.034	pure
CY2024	esla	Effective Income Tax Rate Reconciliation Acquired Intangible EffectiveIncomeTaxRateReconciliationAcquiredIntangible	0.044	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.019	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.006	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.263	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.216	pure
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1838655	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	354895	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	336	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	93183	usd
CY2024Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2640159	usd
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2111518	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4479150	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2559596	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4479150	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2559596	usd
CY2024Q2	esla	Deferred Tax Assets Operating Loss Carryforwards Federal DeferredTaxAssetsOperatingLossCarryforwardsFederal	6600000	usd
CY2023Q2	esla	Deferred Tax Assets Operating Loss Carryforwards Federal DeferredTaxAssetsOperatingLossCarryforwardsFederal	1700000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	6500000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	6500000	usd
CY2024	esla	Effective Income Tax Rate Reconciliation Valuation Allowance Percentage EffectiveIncomeTaxRateReconciliationValuationAllowancePercentage	1	pure
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2600000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4500000	usd
CY2024	esla	Amortized Income Tax Purposes Period AmortizedIncomeTaxPurposesPeriod	P5Y
CY2024	us-gaap	Payments For Rent PaymentsForRent	20000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	22000	usd
CY2024	us-gaap	Payment For Management Fee PaymentForManagementFee	50000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2024Q2	esla	Extension Note Receivable Current ExtensionNoteReceivableCurrent		usd
CY2024Q2	us-gaap	Deferred Costs DeferredCosts		usd
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-36.35
CY2023	esla	Stock Issued During Period Value Recapitalization StockIssuedDuringPeriodValueRecapitalization		usd
CY2024	esla	Issuance Of Series A Preferred Preferred Stock IssuanceOfSeriesAPreferredPreferredStock		usd
CY2024	esla	Stock Issued During Period Value Pipe Investment StockIssuedDuringPeriodValuePIPEInvestment		usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets		usd
CY2024	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther		usd
CY2023	esla	Proceeds From Cash Released From Trust Account ProceedsFromCashReleasedFromTrustAccount		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023	esla	Payment Of Redemption Payable PaymentOfRedemptionPayable		usd
CY2023	esla	Proceeds From Business Combination ProceedsFromBusinessCombination		usd
CY2023	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity		usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1		usd
CY2024	esla	Recognitionof Related Party Operating Rightofuse Asset And Lease Liability RecognitionofRelatedPartyOperatingRightofuseAssetAndLeaseLiability		usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1		usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares		shares
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent		pure
CY2023	esla	Effective Income Tax Rate Reconciliation Acquired Intangible EffectiveIncomeTaxRateReconciliationAcquiredIntangible		pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits		pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves		usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001844417

Files In Submission

Name	View Source	Status
0001213900-24-082374-index-headers.html	Edgar Link	pending
0001213900-24-082374-index.html	Edgar Link	pending
0001213900-24-082374.txt	Edgar Link	pending
0001213900-24-082374-xbrl.zip	Edgar Link	pending
ea0212338-10k_estrella.htm	Edgar Link	pending
ea021233801ex31-1_estrella.htm	Edgar Link	pending
ea021233801ex31-2_estrella.htm	Edgar Link	pending
ea021233801ex32-1_estrella.htm	Edgar Link	pending
ea021233801ex32-2_estrella.htm	Edgar Link	pending
ea021233801ex4-5_estrella.htm	Edgar Link	pending
ea021233801ex97-1_estrella.htm	Edgar Link	pending
esla-20240630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
image_028.jpg	Edgar Link	pending
image_029.jpg	Edgar Link	pending
image_030.jpg	Edgar Link	pending
image_031.jpg	Edgar Link	pending
esla-20240630_def.xml	Edgar Link	unprocessable
esla-20240630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0212338-10k_estrella_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
esla-20240630_cal.xml	Edgar Link	unprocessable
esla-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESLA
Estrella Immunopharma, Inc. Stock $esla

2024 Q3 Form 10-K Financial Statement

#000121390024082374 Filed on September 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESLA Estrella Immunopharma, Inc. Stock $esla

2024 Q3 Form 10-K Financial Statement

#000121390024082374 Filed on September 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESLA
Estrella Immunopharma, Inc. Stock $esla